(Q43816270)

27 November 2017

title

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist (English)

1 reference

27 November 2017

3

1 reference

27 November 2017

4

G M Besser

1 reference

27 November 2017

10

M L Vance

1 reference

27 November 2017

A J van der Lely

1

1 reference

27 November 2017

R K Hutson

2

1 reference

27 November 2017

A L Barkan

5

1 reference

27 November 2017

L Katznelson

6

1 reference

27 November 2017

A Klibanski

7

1 reference

27 November 2017

V Herman-Bonert

8

1 reference

27 November 2017

S Melmed

9

1 reference

27 November 2017

P U Freda

11

1 reference

27 November 2017

P M Stewart

12

1 reference

27 November 2017

K E Friend

13

1 reference

27 November 2017

D R Clemmons

14

1 reference

27 November 2017

G Johannsson

15

1 reference

27 November 2017

S Stavrou

16

1 reference

27 November 2017

D M Cook

17

1 reference

27 November 2017

L S Phillips

18

1 reference

27 November 2017

C J Strasburger

19

1 reference

27 November 2017

S Hackett

20

1 reference

27 November 2017

K A Zib

21

1 reference

27 November 2017

R J Davis

22

1 reference

27 November 2017

J A Scarlett

23

1 reference

27 November 2017

M O Thorner

24

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

27 November 2017

1 reference

27 November 2017

volume

358

1 reference

27 November 2017

issue

9295

1 reference

27 November 2017

page(s)

1754-1759

1 reference

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

The role of radiotherapy in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Rational design of potent antagonists to the human growth hormone receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

The human growth hormone antagonist B2036 does not interact with the prolactin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

1 reference

7 January 2021

Treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Volume of pituitary macroadenomas: assessment by MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906844-1

7 January 2021

10.1016/S0140-6736(01)06844-1

Identifiers

DOI

1 reference

27 November 2017

1 reference